Locate everything for your pharmaceutical industry needs.
 
Locate everything for your pharmaceutical industry needs.

Pharmaceuticals: Company Forest Pharmaceutical

Music of Nature in the Forest, by In the Forest --
The Forest on Fire/Princess Hundred Flowers, by Peking Opera Company --
Sounds Of The Tropical Rain Forest, by Gentle persuasion and The Sounds Of Nature --
The Forest on Fire/Princess Hundred Flowers, by Peking Opera Company -- $15.98
Introduction This analysis examines the historical and forecast performance for Forest in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.
Underappreciated Forest Labs continues its trend of strong growth.
For some reason, most pharmaceutical investors never seem to have much enthusiasm for Forest Laboratories (NYSE: FRX - News). Maybe it's because Forest's drugs aren't sexy biologics or aren't used to treat diseases like cancer. Yet Forest is extremely well run, and its management has shown an ability to overcome numerous obstacles over the past two years.
A Danish pharmaceutical company, H. Lundbeck A/S, maker of the antidepressant Lexapro, is putting its U.S. commercial headquarters, with 50 to 75 employees, in the Philadelphia area, officials said yesterday.
By Linda Loyd, The Philadelphia Inquirer Oct. 17--A Danish pharmaceutical company, H. Lundbeck A/S, maker of the antidepressant Lexapro, is putting its U.S. commercial headquarters, with 50 to 75 employees, in the Philadelphia area, officials said today.
CINCINNATI----Today's "Behind the Headlines" from Schaeffer's Investment Research focuses on Forest Laboratories , Lear , Merrill Lynch , and Pfizer . "Behind the Headlines" is a report that analyzes newsworthy stocks that are generating a lot of attention on Wall Street.
Corrects paragraph 9 to note that Forest's promotion partner in selling Benicar is Daiichi Sankyo Co., not Takeda Pharmaceutical Co.
CHICAGO, Oct 17 (Reuters) - Forest Laboratories on Tuesday said fiscal second-quarter earnings rose 18 percent on higher revenue from drugs to treat depression and Alzheimer's disease, and its raised its 2007 forecast.
Forest Laboratories, Inc. , an international pharmaceutical manufacturer and marketer, today announced that fully diluted earnings per share equaled $0.75 in the second quarter of fiscal 2007, an increase of 27% over last year's second quarter's fully diluted earnings per share of $0.59.
Auckland, Tuesday 17 October, 2006: Scientists and Engineers from a private New Zealand research company have scored an international breakthrough by developing the ability to store and execute computer programmes within a microscopic DNA Pharmaceutical crystal .

Add your Comment